Effect of nitric oxide deficiency on the pulmonary PTHrP system

Bastian Brockhoff, Rolf Schreckenberg, Svenja Forst, Jacqueline Heger, Péter Bencsik, Krisztina Kiss, P. Ferdinándy, Rainer Schulz, Klaus Dieter Schlüter

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Nitric oxide (NO) deficiency is common in pulmonary diseases, but its effect on pulmonary remodelling is still controversial. As pulmonary parathyroid hormone-related protein (PTHrP) expression is a key regulator of pulmonary fibrosis and development, the effect of chronic NO deficiency on the pulmonary PTHrP system and its relationship with oxidative stress was addressed. NO bioavailability in adult rats was reduced by systemic administration of L-NAME via tap water. To clarify the role of NO synthase (NOS)-3-derived NO on pulmonary expression of PTHrP, NOS-3-deficient mice were used. Captopril and hydralazine were used to reduce the hypertensive effect of L-NAME treatment and to interfere with the pulmonary renin-angiotensin system (RAS). Quantitative RT-PCR and immunoblot techniques were used to characterize the expression of key proteins involved in pulmonary remodelling. L-NAME administration significantly reduced pulmonary NO concentration and caused oxidative stress as characterized by increased pulmonary nitrite concentration and increased expression of NOX2, p47phox and p67phox. Furthermore, L-NAME induced the pulmonary expression of PTHrP and of its corresponding receptor, PTH-1R. Expression of PTHrP and PTH-1R correlated with the expression of two well-established PTHrP downstream targets, ADRP and PPARγ, suggesting an activation of the pulmonary PTHrP system by NO deficiency. Captopril reduced the expression of PTHrP, profibrotic markers and ornithine decarboxylase, but neither that of PTH-1R nor that of ADRP and PPARγ. All transcriptional changes were confirmed in NOS-3-deficient mice. In conclusion, NOS-3-derived NO suppresses pulmonary PTHrP and PTH-1R expression, thereby modifying pulmonary remodelling.

Original languageEnglish
JournalJournal of Cellular and Molecular Medicine
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Parathyroid Hormone-Related Protein
Nitric Oxide
Lung
NG-Nitroarginine Methyl Ester
Nitric Oxide Synthase
Peroxisome Proliferator-Activated Receptors
Captopril
Oxidative Stress
Hydralazine
Ornithine Decarboxylase
Pulmonary Fibrosis
Renin-Angiotensin System
Nitrites
Biological Availability
Lung Diseases

Keywords

  • ADRP
  • Elastin
  • Lung fibrosis
  • PPARγ

ASJC Scopus subject areas

  • Molecular Medicine
  • Cell Biology

Cite this

Brockhoff, B., Schreckenberg, R., Forst, S., Heger, J., Bencsik, P., Kiss, K., ... Schlüter, K. D. (Accepted/In press). Effect of nitric oxide deficiency on the pulmonary PTHrP system. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.12942

Effect of nitric oxide deficiency on the pulmonary PTHrP system. / Brockhoff, Bastian; Schreckenberg, Rolf; Forst, Svenja; Heger, Jacqueline; Bencsik, Péter; Kiss, Krisztina; Ferdinándy, P.; Schulz, Rainer; Schlüter, Klaus Dieter.

In: Journal of Cellular and Molecular Medicine, 2016.

Research output: Contribution to journalArticle

Brockhoff, B, Schreckenberg, R, Forst, S, Heger, J, Bencsik, P, Kiss, K, Ferdinándy, P, Schulz, R & Schlüter, KD 2016, 'Effect of nitric oxide deficiency on the pulmonary PTHrP system', Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.12942
Brockhoff, Bastian ; Schreckenberg, Rolf ; Forst, Svenja ; Heger, Jacqueline ; Bencsik, Péter ; Kiss, Krisztina ; Ferdinándy, P. ; Schulz, Rainer ; Schlüter, Klaus Dieter. / Effect of nitric oxide deficiency on the pulmonary PTHrP system. In: Journal of Cellular and Molecular Medicine. 2016.
@article{ce526e1728a34a9e9303eed716b8b378,
title = "Effect of nitric oxide deficiency on the pulmonary PTHrP system",
abstract = "Nitric oxide (NO) deficiency is common in pulmonary diseases, but its effect on pulmonary remodelling is still controversial. As pulmonary parathyroid hormone-related protein (PTHrP) expression is a key regulator of pulmonary fibrosis and development, the effect of chronic NO deficiency on the pulmonary PTHrP system and its relationship with oxidative stress was addressed. NO bioavailability in adult rats was reduced by systemic administration of L-NAME via tap water. To clarify the role of NO synthase (NOS)-3-derived NO on pulmonary expression of PTHrP, NOS-3-deficient mice were used. Captopril and hydralazine were used to reduce the hypertensive effect of L-NAME treatment and to interfere with the pulmonary renin-angiotensin system (RAS). Quantitative RT-PCR and immunoblot techniques were used to characterize the expression of key proteins involved in pulmonary remodelling. L-NAME administration significantly reduced pulmonary NO concentration and caused oxidative stress as characterized by increased pulmonary nitrite concentration and increased expression of NOX2, p47phox and p67phox. Furthermore, L-NAME induced the pulmonary expression of PTHrP and of its corresponding receptor, PTH-1R. Expression of PTHrP and PTH-1R correlated with the expression of two well-established PTHrP downstream targets, ADRP and PPARγ, suggesting an activation of the pulmonary PTHrP system by NO deficiency. Captopril reduced the expression of PTHrP, profibrotic markers and ornithine decarboxylase, but neither that of PTH-1R nor that of ADRP and PPARγ. All transcriptional changes were confirmed in NOS-3-deficient mice. In conclusion, NOS-3-derived NO suppresses pulmonary PTHrP and PTH-1R expression, thereby modifying pulmonary remodelling.",
keywords = "ADRP, Elastin, Lung fibrosis, PPARγ",
author = "Bastian Brockhoff and Rolf Schreckenberg and Svenja Forst and Jacqueline Heger and P{\'e}ter Bencsik and Krisztina Kiss and P. Ferdin{\'a}ndy and Rainer Schulz and Schl{\"u}ter, {Klaus Dieter}",
year = "2016",
doi = "10.1111/jcmm.12942",
language = "English",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Effect of nitric oxide deficiency on the pulmonary PTHrP system

AU - Brockhoff, Bastian

AU - Schreckenberg, Rolf

AU - Forst, Svenja

AU - Heger, Jacqueline

AU - Bencsik, Péter

AU - Kiss, Krisztina

AU - Ferdinándy, P.

AU - Schulz, Rainer

AU - Schlüter, Klaus Dieter

PY - 2016

Y1 - 2016

N2 - Nitric oxide (NO) deficiency is common in pulmonary diseases, but its effect on pulmonary remodelling is still controversial. As pulmonary parathyroid hormone-related protein (PTHrP) expression is a key regulator of pulmonary fibrosis and development, the effect of chronic NO deficiency on the pulmonary PTHrP system and its relationship with oxidative stress was addressed. NO bioavailability in adult rats was reduced by systemic administration of L-NAME via tap water. To clarify the role of NO synthase (NOS)-3-derived NO on pulmonary expression of PTHrP, NOS-3-deficient mice were used. Captopril and hydralazine were used to reduce the hypertensive effect of L-NAME treatment and to interfere with the pulmonary renin-angiotensin system (RAS). Quantitative RT-PCR and immunoblot techniques were used to characterize the expression of key proteins involved in pulmonary remodelling. L-NAME administration significantly reduced pulmonary NO concentration and caused oxidative stress as characterized by increased pulmonary nitrite concentration and increased expression of NOX2, p47phox and p67phox. Furthermore, L-NAME induced the pulmonary expression of PTHrP and of its corresponding receptor, PTH-1R. Expression of PTHrP and PTH-1R correlated with the expression of two well-established PTHrP downstream targets, ADRP and PPARγ, suggesting an activation of the pulmonary PTHrP system by NO deficiency. Captopril reduced the expression of PTHrP, profibrotic markers and ornithine decarboxylase, but neither that of PTH-1R nor that of ADRP and PPARγ. All transcriptional changes were confirmed in NOS-3-deficient mice. In conclusion, NOS-3-derived NO suppresses pulmonary PTHrP and PTH-1R expression, thereby modifying pulmonary remodelling.

AB - Nitric oxide (NO) deficiency is common in pulmonary diseases, but its effect on pulmonary remodelling is still controversial. As pulmonary parathyroid hormone-related protein (PTHrP) expression is a key regulator of pulmonary fibrosis and development, the effect of chronic NO deficiency on the pulmonary PTHrP system and its relationship with oxidative stress was addressed. NO bioavailability in adult rats was reduced by systemic administration of L-NAME via tap water. To clarify the role of NO synthase (NOS)-3-derived NO on pulmonary expression of PTHrP, NOS-3-deficient mice were used. Captopril and hydralazine were used to reduce the hypertensive effect of L-NAME treatment and to interfere with the pulmonary renin-angiotensin system (RAS). Quantitative RT-PCR and immunoblot techniques were used to characterize the expression of key proteins involved in pulmonary remodelling. L-NAME administration significantly reduced pulmonary NO concentration and caused oxidative stress as characterized by increased pulmonary nitrite concentration and increased expression of NOX2, p47phox and p67phox. Furthermore, L-NAME induced the pulmonary expression of PTHrP and of its corresponding receptor, PTH-1R. Expression of PTHrP and PTH-1R correlated with the expression of two well-established PTHrP downstream targets, ADRP and PPARγ, suggesting an activation of the pulmonary PTHrP system by NO deficiency. Captopril reduced the expression of PTHrP, profibrotic markers and ornithine decarboxylase, but neither that of PTH-1R nor that of ADRP and PPARγ. All transcriptional changes were confirmed in NOS-3-deficient mice. In conclusion, NOS-3-derived NO suppresses pulmonary PTHrP and PTH-1R expression, thereby modifying pulmonary remodelling.

KW - ADRP

KW - Elastin

KW - Lung fibrosis

KW - PPARγ

UR - http://www.scopus.com/inward/record.url?scp=84984674660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984674660&partnerID=8YFLogxK

U2 - 10.1111/jcmm.12942

DO - 10.1111/jcmm.12942

M3 - Article

C2 - 27581501

AN - SCOPUS:84984674660

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

ER -